MX2020007338A - Composiciones y métodos para el direccionamiento a tipos de cáncer que expresan clec12a. - Google Patents

Composiciones y métodos para el direccionamiento a tipos de cáncer que expresan clec12a.

Info

Publication number
MX2020007338A
MX2020007338A MX2020007338A MX2020007338A MX2020007338A MX 2020007338 A MX2020007338 A MX 2020007338A MX 2020007338 A MX2020007338 A MX 2020007338A MX 2020007338 A MX2020007338 A MX 2020007338A MX 2020007338 A MX2020007338 A MX 2020007338A
Authority
MX
Mexico
Prior art keywords
disclosed
clec12a
methods
expressing
compositions
Prior art date
Application number
MX2020007338A
Other languages
English (en)
Inventor
Marco L Davila
Original Assignee
H Lee Moffitt Cancer Ct & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lee Moffitt Cancer Ct & Res filed Critical H Lee Moffitt Cancer Ct & Res
Publication of MX2020007338A publication Critical patent/MX2020007338A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se divulgan composiciones y métodos para el tratamiento dirigido de tipos de cáncer que expresan CLEC12A; en particular, se divulgan polipéptidos de receptor de antígeno quimérico (CAR) que pueden usarse con transferencia adoptiva de células para el direccionamiento a, y la erradicación de, tipos de cáncer que expresan CLEC12A; también se divulgan células efectoras inmunitarias, tales como linfocitos T o células Natural Killer (NK), que están diseñadas por ingeniería genética para expresar estos CAR; por lo tanto, también se divulgan métodos para proporcionar una inmunidad antitumoral en un sujeto con un tipo de cáncer que expresa CLEC12A que implica la transferencia adoptiva de las células efectoras inmunitarias divulgadas que están diseñadas por ingeniería genética para expresar los CAR divulgados; también se divulgan anticuerpos multivalentes que son capaces de activar los linfocitos T para que destruyan las células malignas que expresan CLEC12A.
MX2020007338A 2018-01-09 2019-01-08 Composiciones y métodos para el direccionamiento a tipos de cáncer que expresan clec12a. MX2020007338A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862615096P 2018-01-09 2018-01-09
US201862654623P 2018-04-09 2018-04-09
US201862654621P 2018-04-09 2018-04-09
US201862730397P 2018-09-12 2018-09-12
US201862730390P 2018-09-12 2018-09-12
US201862767865P 2018-11-15 2018-11-15
US201862767859P 2018-11-15 2018-11-15
PCT/US2019/012664 WO2019139888A1 (en) 2018-01-09 2019-01-08 Compositions and methods for targeting clec12a-expressing cancers

Publications (1)

Publication Number Publication Date
MX2020007338A true MX2020007338A (es) 2020-11-06

Family

ID=67219811

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007338A MX2020007338A (es) 2018-01-09 2019-01-08 Composiciones y métodos para el direccionamiento a tipos de cáncer que expresan clec12a.

Country Status (9)

Country Link
US (1) US11951129B2 (es)
EP (1) EP3737400A4 (es)
JP (1) JP7315244B2 (es)
CN (1) CN111867613A (es)
AU (1) AU2019207635A1 (es)
BR (1) BR112020013954A2 (es)
CA (1) CA3088878A1 (es)
MX (1) MX2020007338A (es)
WO (1) WO2019139888A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116479022A (zh) * 2018-12-12 2023-07-25 中南大学 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
CA3224385A1 (en) * 2019-08-16 2021-02-25 H. Lee Moffitt Cancer Center And Research Institute Inc. Chimeric antigen receptors for treating myeloid malignancies
WO2021050862A1 (en) * 2019-09-13 2021-03-18 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting cd371 and uses thereof
WO2021076545A1 (en) * 2019-10-17 2021-04-22 Regents Of The University Of Minnesota Clec12a antibody fragment sequences and methods
US20230257477A1 (en) * 2020-07-02 2023-08-17 H. Lee Moffitt Cancer Center And Research Institute Inc. Dual chimeric antigen receptor t cells targeting ccd99- and clec12a-expressing cancers
CN113980134B (zh) 2020-12-11 2022-05-31 广州百暨基因科技有限公司 抗cll1抗体及其应用
CN113234169B (zh) 2020-12-11 2022-11-01 广州百暨基因科技有限公司 靶向cll1嵌合抗原受体及其应用
CA3216770A1 (en) * 2021-04-26 2022-11-03 Tomoki Yoshihara Anti-clec12a antibodies and uses thereof
BR112023022297A2 (pt) 2021-04-26 2023-12-26 Memorial Hospital For Cancer And Allied Diseases Receptores quiméricos que alvejam adgre2 e/ou clec12a e usos dos mesmos
WO2023002390A1 (en) * 2021-07-20 2023-01-26 Abl Bio Inc. Anti-cll-1 antibodies and uses thereof
CN117693528A (zh) * 2021-07-30 2024-03-12 南京传奇生物科技有限公司 抗cll1抗体及其构建体
WO2023225641A2 (en) * 2022-05-20 2023-11-23 H. Lee Moffitt Cancer Center And Research Institute Inc. Compositions and methods for targeting clec12a-expressing cancers
CN117736327B (zh) * 2023-11-29 2024-11-26 四川大学 靶向clec12a同种异体通用car-t细胞的制备及用途
CN118496363B (zh) * 2024-04-18 2025-02-14 苏州系统医学研究所 靶向clec12a抗体和嵌合抗原受体t细胞的制备及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA2347067C (en) 1998-03-31 2013-09-17 Geron Corporation Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US6713055B2 (en) 2000-11-27 2004-03-30 Geron Corporation Glycosyltransferase vectors for treating cancer
EP1400534B1 (en) 2002-09-10 2015-10-28 Affimed GmbH Human CD3-specific antibody with immunosuppressive properties
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
US8124076B2 (en) 2005-08-18 2012-02-28 Ramot At Tel Aviv University Ltd. Single chain antibodies against β-amyloid peptide
BRPI0919377A2 (pt) 2008-09-26 2016-09-27 Dana Farber Cancer Inst Inc anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
CN104462128B (zh) 2013-09-22 2018-04-13 腾讯科技（深圳）有限公司 多媒体文件处理的方法、装置和终端设备
KR102225489B1 (ko) 2013-12-17 2021-03-10 제넨테크, 인크. 항-cd3 항체 및 이의 사용 방법
JP2017513818A (ja) * 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
JP6736540B2 (ja) 2014-07-21 2020-08-05 ノバルティス アーゲー Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置
US20180002435A1 (en) 2015-01-26 2018-01-04 Cellectis mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLS
CA3004743A1 (en) 2015-11-24 2017-06-01 Cellerant Therapeutics, Inc. Humanized anti-cll-1 antibodies
CN111116753A (zh) 2018-10-30 2020-05-08 上海泰因生物技术有限公司 一种双特异性抗体的制备方法

Also Published As

Publication number Publication date
US20200345779A1 (en) 2020-11-05
US11951129B2 (en) 2024-04-09
AU2019207635A1 (en) 2020-08-06
EP3737400A4 (en) 2021-10-27
BR112020013954A2 (pt) 2020-12-01
CN111867613A (zh) 2020-10-30
JP2021509817A (ja) 2021-04-08
WO2019139888A1 (en) 2019-07-18
EP3737400A1 (en) 2020-11-18
CA3088878A1 (en) 2019-07-18
JP7315244B2 (ja) 2023-07-26

Similar Documents

Publication Publication Date Title
MX2020007338A (es) Composiciones y métodos para el direccionamiento a tipos de cáncer que expresan clec12a.
MX2020007281A (es) Composiciones y métodos que se dirigen a cánceres que expresan cd99.
MX2019006598A (es) Celulas asesinas naturales modificadas geneticamente y sus usos.
MX2019015484A (es) Receptores quiméricos de antígeno con dominios coestimuladores cd28 mutados.
MX2021013368A (es) Celulas t del receptor de antigenos quimericos focalizadas a cd19 especificas del antigeno.
CL2019000326A1 (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos
MX2019003886A (es) Receptores de antigenos quimericos para el tratamiento del cancer.
MX2020004741A (es) Nuevos receptores de las celulas t modificados geneticamente y terapias immunologicas que emplean los mismos.
MX2020000686A (es) Composiciones y métodos para el direccionamiento de cánceres que expresan cd33.
ECSP17064523A (es) Composiciones y métodos para activar la señalización dependiente del "estimulador del gen de interferon"
MX2025010469A (es) Composiciones de vcar y metodos de uso
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
MX2017000646A (es) Celulas geneticamente modificadas para terapia celular adoptiva.
BR112015027567A2 (pt) polipeptídeo, sequência de ácido nucleico isolada, célula, método de fornecimento de uma imunidade antitumoral
MX2019000643A (es) Receptores de antigenos quimericos y metodos de uso.
CO2017010502A2 (es) Receptores del antígeno quimérico dirigidos al antígeno de maduración de células b
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
MX2018007295A (es) Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos.
MX2017005344A (es) Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
MX2020004910A (es) Composiciones y métodos para el agotamiento de células cd5 +.
MX2015010836A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno anti egfrviii humanizado.
CU24437B1 (es) Anticuerpos agonistas de anti-gitr y composiciones de los mismos
MX2016016288A (es) Polipeptidos efectores de la subunidad a de la toxina shiga resistentes a la disociacion por proteasa y moleculas dirigidas a las celulas que los comprenden.